| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 20 | 2019 | 249 | 4.670 |
Why?
|
| Kidney Failure, Chronic | 31 | 2019 | 540 | 4.060 |
Why?
|
| Renal Dialysis | 18 | 2019 | 279 | 3.780 |
Why?
|
| Mucin-1 | 9 | 2019 | 13 | 2.820 |
Why?
|
| Nephrology | 8 | 2015 | 33 | 2.740 |
Why?
|
| Mutation | 23 | 2021 | 487 | 2.720 |
Why?
|
| Mucoproteins | 10 | 2015 | 13 | 2.290 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 8 | 2019 | 11 | 2.090 |
Why?
|
| Serum Albumin | 7 | 2012 | 54 | 1.500 |
Why?
|
| Humans | 101 | 2021 | 31836 | 1.460 |
Why?
|
| Nephritis, Interstitial | 5 | 2018 | 9 | 1.350 |
Why?
|
| Kidney Transplantation | 8 | 2018 | 515 | 1.330 |
Why?
|
| Male | 71 | 2021 | 19091 | 1.300 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2018 | 835 | 1.260 |
Why?
|
| Gout | 6 | 2015 | 14 | 1.190 |
Why?
|
| Diabetic Nephropathies | 9 | 2019 | 224 | 1.170 |
Why?
|
| Middle Aged | 43 | 2019 | 11824 | 1.160 |
Why?
|
| Uric Acid | 6 | 2015 | 26 | 1.160 |
Why?
|
| Renin | 4 | 2020 | 109 | 1.140 |
Why?
|
| Kidney | 13 | 2019 | 515 | 1.130 |
Why?
|
| Hyperuricemia | 7 | 2015 | 11 | 1.120 |
Why?
|
| Anti-Bacterial Agents | 5 | 2013 | 300 | 1.110 |
Why?
|
| Anemia | 6 | 2020 | 59 | 1.080 |
Why?
|
| Female | 61 | 2021 | 19859 | 1.070 |
Why?
|
| Catheters, Indwelling | 4 | 2014 | 42 | 1.030 |
Why?
|
| Sickle Cell Trait | 3 | 2017 | 14 | 1.020 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2020 | 5 | 0.980 |
Why?
|
| Adult | 31 | 2021 | 9327 | 0.950 |
Why?
|
| Bacteremia | 3 | 2011 | 58 | 0.940 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 288 | 0.930 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2019 | 63 | 0.900 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2013 | 5 | 0.860 |
Why?
|
| Genetic Testing | 4 | 2019 | 96 | 0.860 |
Why?
|
| Kidney Diseases, Cystic | 4 | 2019 | 13 | 0.840 |
Why?
|
| Diabetes Mellitus | 4 | 2010 | 409 | 0.830 |
Why?
|
| Thrombosis | 4 | 2019 | 72 | 0.770 |
Why?
|
| Catheterization, Central Venous | 3 | 2014 | 62 | 0.730 |
Why?
|
| Aged | 36 | 2019 | 10288 | 0.730 |
Why?
|
| Rare Diseases | 1 | 2019 | 20 | 0.680 |
Why?
|
| Pancreatic Elastase | 1 | 2019 | 4 | 0.670 |
Why?
|
| Glomerular Filtration Rate | 9 | 2018 | 305 | 0.660 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2019 | 24 | 0.660 |
Why?
|
| Radial Artery | 1 | 2019 | 16 | 0.660 |
Why?
|
| Veins | 1 | 2019 | 29 | 0.660 |
Why?
|
| Minocycline | 2 | 2011 | 11 | 0.650 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2018 | 3 | 0.650 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2018 | 4 | 0.650 |
Why?
|
| Vascular Patency | 1 | 2019 | 69 | 0.650 |
Why?
|
| Urolithiasis | 1 | 2018 | 7 | 0.650 |
Why?
|
| Peritoneal Dialysis | 4 | 2013 | 26 | 0.640 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2019 | 48 | 0.640 |
Why?
|
| Kidney Calculi | 1 | 2018 | 23 | 0.640 |
Why?
|
| Upper Extremity | 1 | 2019 | 57 | 0.630 |
Why?
|
| Water-Electrolyte Balance | 3 | 2013 | 16 | 0.630 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 31 | 0.620 |
Why?
|
| Referral and Consultation | 1 | 2019 | 140 | 0.610 |
Why?
|
| Child | 14 | 2021 | 2425 | 0.610 |
Why?
|
| Carrier Proteins | 1 | 2019 | 137 | 0.610 |
Why?
|
| Adolescent | 16 | 2021 | 3511 | 0.600 |
Why?
|
| Risk Factors | 19 | 2014 | 3851 | 0.590 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 2 | 0.580 |
Why?
|
| Urate Oxidase | 2 | 2015 | 2 | 0.580 |
Why?
|
| Nephritis, Hereditary | 1 | 2017 | 3 | 0.580 |
Why?
|
| Quality of Life | 2 | 2019 | 924 | 0.560 |
Why?
|
| Equipment Contamination | 2 | 2007 | 11 | 0.550 |
Why?
|
| Kidney Tubules | 2 | 2019 | 26 | 0.530 |
Why?
|
| Young Adult | 10 | 2021 | 2603 | 0.520 |
Why?
|
| Gout Suppressants | 1 | 2015 | 4 | 0.510 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 64 | 0.500 |
Why?
|
| Albuminuria | 6 | 2014 | 181 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2014 | 15 | 0.490 |
Why?
|
| Hypertension | 8 | 2014 | 956 | 0.490 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 23 | 0.490 |
Why?
|
| Cardiovascular Diseases | 9 | 2012 | 1122 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 38 | 0.480 |
Why?
|
| Glomerulonephritis | 2 | 2013 | 21 | 0.460 |
Why?
|
| Nephrotic Syndrome | 2 | 2017 | 13 | 0.460 |
Why?
|
| Hemodialysis Solutions | 1 | 2013 | 4 | 0.450 |
Why?
|
| Peritoneal Fibrosis | 1 | 2013 | 1 | 0.450 |
Why?
|
| Device Removal | 1 | 2013 | 33 | 0.430 |
Why?
|
| Arthritis, Infectious | 1 | 2013 | 24 | 0.430 |
Why?
|
| Siblings | 2 | 2013 | 25 | 0.420 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2012 | 2 | 0.420 |
Why?
|
| Death, Sudden | 1 | 2012 | 8 | 0.420 |
Why?
|
| Hypophosphatemia | 1 | 2012 | 5 | 0.410 |
Why?
|
| Renal Replacement Therapy | 1 | 2012 | 18 | 0.410 |
Why?
|
| Societies, Medical | 4 | 2013 | 161 | 0.410 |
Why?
|
| Diabetes Complications | 2 | 2010 | 177 | 0.400 |
Why?
|
| Knee Joint | 1 | 2013 | 142 | 0.400 |
Why?
|
| Retrospective Studies | 10 | 2019 | 3488 | 0.400 |
Why?
|
| Risk Assessment | 10 | 2019 | 1431 | 0.390 |
Why?
|
| Hospitalization | 2 | 2012 | 463 | 0.390 |
Why?
|
| Vital Signs | 1 | 2011 | 7 | 0.390 |
Why?
|
| African Americans | 5 | 2011 | 1428 | 0.390 |
Why?
|
| Pedigree | 7 | 2021 | 140 | 0.380 |
Why?
|
| Acetates | 2 | 2008 | 10 | 0.380 |
Why?
|
| Calcium | 1 | 2013 | 304 | 0.380 |
Why?
|
| Polyamines | 2 | 2008 | 11 | 0.380 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2010 | 35 | 0.370 |
Why?
|
| Coronary Disease | 4 | 2007 | 213 | 0.360 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 1527 | 0.360 |
Why?
|
| Family Health | 1 | 2010 | 76 | 0.350 |
Why?
|
| Hyperglycemia | 1 | 2010 | 84 | 0.340 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 65 | 0.340 |
Why?
|
| European Continental Ancestry Group | 3 | 2011 | 1169 | 0.340 |
Why?
|
| Biopsy | 5 | 2019 | 260 | 0.330 |
Why?
|
| Hyperphosphatemia | 1 | 2008 | 6 | 0.330 |
Why?
|
| Time Factors | 6 | 2019 | 2146 | 0.330 |
Why?
|
| Creatinine | 9 | 2019 | 195 | 0.330 |
Why?
|
| Phosphates | 2 | 2012 | 25 | 0.330 |
Why?
|
| Chelating Agents | 1 | 2008 | 17 | 0.330 |
Why?
|
| Congresses as Topic | 3 | 2013 | 40 | 0.320 |
Why?
|
| Prospective Studies | 11 | 2019 | 2277 | 0.310 |
Why?
|
| Immunosuppressive Agents | 4 | 2018 | 238 | 0.300 |
Why?
|
| United States | 9 | 2019 | 3925 | 0.300 |
Why?
|
| Proteinuria | 1 | 2007 | 59 | 0.300 |
Why?
|
| Gene Deletion | 2 | 2004 | 66 | 0.300 |
Why?
|
| Catheterization | 1 | 2007 | 58 | 0.290 |
Why?
|
| Mitochondria | 2 | 2021 | 186 | 0.290 |
Why?
|
| Dialysis Solutions | 1 | 2007 | 6 | 0.290 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 132 | 0.290 |
Why?
|
| Disease Progression | 7 | 2019 | 593 | 0.280 |
Why?
|
| Child, Preschool | 5 | 2018 | 1259 | 0.270 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2005 | 2 | 0.260 |
Why?
|
| Parathyroidectomy | 1 | 2005 | 15 | 0.260 |
Why?
|
| Edetic Acid | 1 | 2005 | 8 | 0.260 |
Why?
|
| Treatment Outcome | 7 | 2019 | 3294 | 0.260 |
Why?
|
| Antimetabolites | 2 | 2018 | 11 | 0.250 |
Why?
|
| Allopurinol | 2 | 2018 | 12 | 0.250 |
Why?
|
| North Carolina | 6 | 2019 | 1514 | 0.250 |
Why?
|
| Hemoglobin, Sickle | 2 | 2017 | 8 | 0.240 |
Why?
|
| Cohort Studies | 8 | 2020 | 1824 | 0.240 |
Why?
|
| Carotid Artery Diseases | 1 | 2005 | 114 | 0.240 |
Why?
|
| Calcinosis | 1 | 2005 | 145 | 0.240 |
Why?
|
| Hospital Mortality | 2 | 2019 | 190 | 0.240 |
Why?
|
| Cause of Death | 4 | 2019 | 238 | 0.240 |
Why?
|
| Longitudinal Studies | 7 | 2013 | 771 | 0.240 |
Why?
|
| Kidney Medulla | 1 | 2004 | 29 | 0.240 |
Why?
|
| Genes, Dominant | 4 | 2016 | 27 | 0.230 |
Why?
|
| Age Factors | 5 | 2014 | 1187 | 0.220 |
Why?
|
| Infant | 4 | 2021 | 1055 | 0.220 |
Why?
|
| Phenotype | 5 | 2019 | 635 | 0.220 |
Why?
|
| Urine | 2 | 2019 | 64 | 0.210 |
Why?
|
| Double-Blind Method | 2 | 2019 | 523 | 0.210 |
Why?
|
| Kidney Function Tests | 3 | 2012 | 106 | 0.210 |
Why?
|
| Purine-Pyrimidine Metabolism, Inborn Errors | 2 | 2019 | 2 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 756 | 0.190 |
Why?
|
| Academic Medical Centers | 3 | 2011 | 156 | 0.190 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2021 | 3 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 135 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 351 | 0.190 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 39 | 0.190 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 72 | 0.190 |
Why?
|
| Aged, 80 and over | 8 | 2014 | 3988 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2011 | 1067 | 0.180 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 137 | 0.180 |
Why?
|
| Renal Insufficiency | 3 | 2006 | 58 | 0.180 |
Why?
|
| Molecular Motor Proteins | 2 | 2011 | 58 | 0.180 |
Why?
|
| Registries | 3 | 2019 | 295 | 0.180 |
Why?
|
| Peptide Synthases | 1 | 2019 | 1 | 0.180 |
Why?
|
| Carboxy-Lyases | 1 | 2019 | 4 | 0.180 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 89 | 0.180 |
Why?
|
| Purines | 1 | 2019 | 21 | 0.170 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 12 | 0.170 |
Why?
|
| Vesicular Transport Proteins | 1 | 2019 | 10 | 0.170 |
Why?
|
| Heterozygote | 2 | 2016 | 57 | 0.170 |
Why?
|
| Lysosomes | 1 | 2019 | 10 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 17 | 0.170 |
Why?
|
| Benzamides | 1 | 2019 | 49 | 0.170 |
Why?
|
| Algorithms | 2 | 2014 | 495 | 0.170 |
Why?
|
| Antisocial Personality Disorder | 1 | 2018 | 2 | 0.170 |
Why?
|
| Kidney Calices | 1 | 2019 | 4 | 0.160 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 7 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 13 | 0.160 |
Why?
|
| Diverticulum | 1 | 2019 | 11 | 0.160 |
Why?
|
| Violence | 1 | 2018 | 15 | 0.160 |
Why?
|
| Ribose-Phosphate Pyrophosphokinase | 1 | 2018 | 1 | 0.160 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 7 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 140 | 0.160 |
Why?
|
| Maxillary Fractures | 1 | 2018 | 4 | 0.150 |
Why?
|
| Maxilla | 1 | 2018 | 10 | 0.150 |
Why?
|
| Maxillofacial Injuries | 1 | 2018 | 9 | 0.150 |
Why?
|
| Lupus Nephritis | 1 | 2018 | 30 | 0.150 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2018 | 17 | 0.150 |
Why?
|
| Internet | 1 | 2019 | 195 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 45 | 0.150 |
Why?
|
| Office Visits | 1 | 2018 | 73 | 0.150 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 45 | 0.150 |
Why?
|
| Hematologic Tests | 1 | 2017 | 10 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 43 | 0.140 |
Why?
|
| Fanconi Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 4 | 0.140 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 874 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2019 | 487 | 0.140 |
Why?
|
| Calcium Compounds | 2 | 2008 | 8 | 0.140 |
Why?
|
| Stem Cells | 1 | 2019 | 312 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 111 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 11 | 0.140 |
Why?
|
| Incidence | 5 | 2018 | 1192 | 0.140 |
Why?
|
| DNA | 1 | 2017 | 227 | 0.140 |
Why?
|
| Blood Group Antigens | 2 | 2006 | 4 | 0.130 |
Why?
|
| Drug Combinations | 2 | 2007 | 93 | 0.130 |
Why?
|
| Prevalence | 4 | 2014 | 979 | 0.130 |
Why?
|
| Cystatins | 2 | 2005 | 8 | 0.130 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 103 | 0.130 |
Why?
|
| Animals | 7 | 2019 | 7450 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 66 | 0.130 |
Why?
|
| Heart Failure | 3 | 2019 | 620 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2015 | 26 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 99 | 0.130 |
Why?
|
| Propensity Score | 1 | 2014 | 39 | 0.120 |
Why?
|
| Systole | 1 | 2014 | 99 | 0.120 |
Why?
|
| Alleles | 3 | 2016 | 248 | 0.120 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 10 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2018 | 895 | 0.120 |
Why?
|
| Veterans | 1 | 2014 | 66 | 0.120 |
Why?
|
| Logistic Models | 3 | 2011 | 777 | 0.110 |
Why?
|
| Prognosis | 3 | 2018 | 1498 | 0.110 |
Why?
|
| Acidosis | 1 | 2013 | 18 | 0.110 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 8 | 0.110 |
Why?
|
| Vomiting | 1 | 2013 | 24 | 0.110 |
Why?
|
| Nausea | 1 | 2013 | 53 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2003 | 30 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 912 | 0.110 |
Why?
|
| Hemodialysis, Home | 1 | 2012 | 13 | 0.100 |
Why?
|
| Magnesium | 1 | 2012 | 30 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2017 | 779 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 2 | 2016 | 24 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 100 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 315 | 0.100 |
Why?
|
| Patient Admission | 1 | 2011 | 60 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2016 | 400 | 0.090 |
Why?
|
| Apoptosis | 2 | 2019 | 354 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 298 | 0.090 |
Why?
|
| Hospital Rapid Response Team | 1 | 2010 | 5 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 531 | 0.090 |
Why?
|
| Patient Selection | 1 | 2012 | 276 | 0.090 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 2 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 244 | 0.090 |
Why?
|
| Safety Management | 1 | 2010 | 37 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2010 | 38 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 72 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2011 | 200 | 0.080 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 251 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 181 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 491 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 398 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 564 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2007 | 6 | 0.080 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2007 | 4 | 0.080 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2007 | 6 | 0.080 |
Why?
|
| Solutions | 1 | 2007 | 35 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 391 | 0.070 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 38 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2021 | 508 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2007 | 26 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 607 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 2271 | 0.070 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 19 | 0.070 |
Why?
|
| H(+)-K(+)-Exchanging ATPase | 1 | 2006 | 20 | 0.070 |
Why?
|
| Survival Rate | 1 | 2009 | 884 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2006 | 124 | 0.070 |
Why?
|
| Brain Infarction | 1 | 2005 | 10 | 0.070 |
Why?
|
| Phenylbutyrates | 1 | 2005 | 4 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2019 | 665 | 0.070 |
Why?
|
| Colchicine | 1 | 2005 | 8 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 18 | 0.070 |
Why?
|
| Protein Subunits | 2 | 2021 | 34 | 0.060 |
Why?
|
| Guanine | 1 | 2005 | 15 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2005 | 48 | 0.060 |
Why?
|
| Adenine | 1 | 2005 | 15 | 0.060 |
Why?
|
| Infection Control | 1 | 2005 | 28 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2005 | 60 | 0.060 |
Why?
|
| Cross Infection | 1 | 2005 | 49 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 74 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2005 | 148 | 0.060 |
Why?
|
| Point Mutation | 1 | 2004 | 26 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2005 | 122 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 155 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2004 | 15 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 899 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2003 | 4 | 0.060 |
Why?
|
| Base Pairing | 1 | 2003 | 4 | 0.060 |
Why?
|
| Sepsis | 1 | 2005 | 158 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 122 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 21 | 0.060 |
Why?
|
| Polyethylenes | 1 | 2003 | 2 | 0.060 |
Why?
|
| Lanthanum | 1 | 2003 | 3 | 0.060 |
Why?
|
| Iron Compounds | 1 | 2003 | 2 | 0.060 |
Why?
|
| Aluminum Compounds | 1 | 2003 | 3 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 39 | 0.060 |
Why?
|
| Ketoglutaric Acids | 1 | 2003 | 5 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2003 | 7 | 0.060 |
Why?
|
| Sequence Alignment | 1 | 2003 | 60 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 80 | 0.060 |
Why?
|
| Calcium Carbonate | 1 | 2003 | 8 | 0.060 |
Why?
|
| Exons | 1 | 2003 | 52 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2005 | 537 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2003 | 43 | 0.060 |
Why?
|
| Blood Coagulation Factors | 1 | 2003 | 2 | 0.050 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 6 | 0.050 |
Why?
|
| Myoglobin | 1 | 2002 | 11 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2003 | 65 | 0.050 |
Why?
|
| Cysteine | 1 | 2003 | 138 | 0.050 |
Why?
|
| Compartment Syndromes | 1 | 2002 | 39 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2013 | 62 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2011 | 470 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2019 | 833 | 0.050 |
Why?
|
| Dementia | 1 | 2004 | 251 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 297 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 23 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2021 | 34 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1424 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2005 | 148 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2021 | 112 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 589 | 0.040 |
Why?
|
| Adenylosuccinate Lyase | 1 | 2019 | 1 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1158 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 4 | 0.040 |
Why?
|
| Autistic Disorder | 1 | 2019 | 8 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2017 | 378 | 0.040 |
Why?
|
| Imidazoline Receptors | 1 | 2019 | 2 | 0.040 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 6 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2019 | 81 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 28 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 15 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 32 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2019 | 15 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 22 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 76 | 0.040 |
Why?
|
| Urography | 1 | 2019 | 15 | 0.040 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2019 | 17 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 114 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 449 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2019 | 184 | 0.040 |
Why?
|
| Arthritis, Gouty | 1 | 2018 | 1 | 0.040 |
Why?
|
| Nephrolithiasis | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 261 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2019 | 142 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2019 | 292 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2018 | 59 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 95 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 513 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 686 | 0.040 |
Why?
|
| Podocytes | 1 | 2017 | 20 | 0.040 |
Why?
|
| Survivors | 1 | 2019 | 159 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 229 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2018 | 91 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 73 | 0.040 |
Why?
|
| Cell Line | 2 | 2009 | 434 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2019 | 598 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2016 | 8 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 58 | 0.030 |
Why?
|
| Neutropenia | 1 | 2016 | 30 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 56 | 0.030 |
Why?
|
| Zebrafish | 1 | 2016 | 23 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 73 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 21 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 34 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 50 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 283 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 193 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 193 | 0.030 |
Why?
|
| Cystatin C | 2 | 2005 | 31 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 766 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2015 | 64 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 85 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2013 | 843 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 255 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 727 | 0.030 |
Why?
|
| Fibrinogen | 2 | 2004 | 43 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 764 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 2476 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 10 | 0.030 |
Why?
|
| C-Reactive Protein | 2 | 2004 | 239 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 220 | 0.030 |
Why?
|
| Comorbidity | 1 | 2013 | 566 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 220 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 58 | 0.020 |
Why?
|
| Atherosclerosis | 2 | 2006 | 767 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 93 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 220 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 196 | 0.020 |
Why?
|
| Risk | 1 | 2007 | 318 | 0.020 |
Why?
|
| Rubidium Radioisotopes | 1 | 2006 | 7 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2006 | 10 | 0.020 |
Why?
|
| Biotinylation | 1 | 2006 | 10 | 0.020 |
Why?
|
| Alanine | 1 | 2006 | 27 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2006 | 96 | 0.020 |
Why?
|
| Colon | 1 | 2006 | 51 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 191 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2006 | 230 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 158 | 0.020 |
Why?
|
| Factor VII | 1 | 2004 | 3 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2004 | 47 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2004 | 57 | 0.020 |
Why?
|
| Dementia, Vascular | 1 | 2004 | 12 | 0.020 |
Why?
|
| Muscles | 1 | 2004 | 62 | 0.010 |
Why?
|
| Chromogranins | 1 | 2003 | 2 | 0.010 |
Why?
|
| Receptors, Erythropoietin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Platelet Activation | 1 | 2003 | 13 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 2004 | 41 | 0.010 |
Why?
|
| Azathioprine | 1 | 2003 | 24 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 49 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 662 | 0.010 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 40 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 95 | 0.010 |
Why?
|
| Intermittent Claudication | 1 | 2003 | 11 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2003 | 64 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 63 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2003 | 46 | 0.010 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 161 | 0.010 |
Why?
|
| Fibrinolysin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 86 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2003 | 18 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 390 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 247 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 120 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 284 | 0.010 |
Why?
|
| Pressure | 1 | 2002 | 51 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 155 | 0.010 |
Why?
|
| Hindlimb | 1 | 2002 | 54 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 196 | 0.010 |
Why?
|
| Korea | 1 | 2002 | 3 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 23 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2003 | 237 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 206 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 177 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 251 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2002 | 173 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 75 | 0.010 |
Why?
|
| Iron | 1 | 2002 | 115 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 327 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 581 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 306 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 1323 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 540 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 1012 | 0.010 |
Why?
|